| Rowcaps |
|---|
| Rows 1-2: | Show the baseline CMR ejection fraction measurements for participant 101 at VISIT 1. | | Row 3: | Shows the baseline NTProbTest for participant 101 at VISIT 1. | | Rows 4-5: | Show the CMR ejection fraction measurements for participant 101 at VISIT 6. | | Row 6: | Shows the NTProbTest for participant 101 at VISIT 6. |
|
| Dataset2 |
|---|
| | Row | STUDYID | USUBJID | ASEQ | BSABASE | PARAM | PARAMCD | PARAMN | AVAL | AVISIT | AVISITN | VISIT | ADT | ABLFL | BASE | CHG | PCHG | CHGCAT1 | TRT01P | ITTFL | AGE | AGEU | SEX | SRCDOM | SRCSEQ |
|---|
| 1 | DMD-EFLGE | DMD-EFLGE-101 | 1 | 0.65 | Left Ventricular Ejection Fraction, Calculated (%) | LVEFC | 1 | 67 | Visit 1 (Month 1) | 1 | VISIT 1 | 16May2022 | Y | 67 |
|
|
| Treatment A | Y | 8 | YEARS | M | CV | 3 | | 2 | DMD-EFLGE | DMD-EFLGE-101 | 2 | 0.65 | Right Ventricular Ejection Fraction, Calculated (%) | RVEFC | 2 | 74 | Visit 1 (Month 1) | 1 | VISIT 1 | 16May2022 | Y | 74 |
|
|
| Treatment A | Y | 8 | YEARS | M | CV | 7 | | 3 | DMD-EFLGE | DMD-EFLGE-101 | 3 | 0.65 | N-Terminal ProB-type Natriuretic Peptide (IU/L) | BNPPRONT | 3 | 40 | Visit 1 (Baseline) | 1 | VISIT 1 | 16May2022 | Y | 40 |
|
|
| Treatment A | Y | 8 | YEARS | M | LB | 1 | | 4 | DMD-EFLGE | DMD-EFLGE-101 | 4 | 0.65 | Left Ventricular Ejection Fraction, Calculated (%) | LVEFC | 1 | 60 | Visit 6 (Month 12) | 6 | VISIT 6 | 01Jun2023 |
| 67 | -7 | -10.447761 | Decline >=10.0 | Treatment A | Y | 8 | YEARS | M | CV | 11 | | 5 | DMD-EFLGE | DMD-EFLGE-101 | 5 | 0.65 | Right Ventricular Ejection Fraction, Calculated (%) | RVEFC | 2 | 61 | Visit 6 (Month 12) | 6 | VISIT 6 | 01Jun2023 |
| 74 | -13 | -17.567568 | Decline >=10.0 | Treatment A | Y | 8 | YEARS | M | CV | 15 | | 6 | DMD-EFLGE | DMD-EFLGE-101 | 6 | 0.65 | N-Terminal ProB-type Natriuretic Peptide (IU/L) | BNPPRONT | 3 | 900 | Visit 6 (1 YearMonth 12) | 6 | VISIT 16 | 1Jun2023 |
| 40 | 860 | 2,150 |
| Treatment A | Y | 8 | YEARS | M | LB | 2 |
|
|